M&A
confidence high
sentiment positive
materiality 0.65
Standard BioTools holders approve Treeline merger, reverse split up to 1-for-40, Mass Cytometry sale
STANDARD BIOTOOLS INC.
- All seven special-meeting proposals passed; share issuance for the Treeline Biosciences merger won 274,099,041 votes for vs 7,571,806 against.
- Charter amendment approved to effect a reverse split of 1-for-20 to 1-for-40, ratio to be mutually agreed with Treeline, and rename the company Treeline Biosciences, Inc.
- Element Mass Cytometry divestiture to Element Biosystems, LLC (a GMT Venture Partners vehicle) approved 276,299,544 to 5,336,020.
- Quorum of 281,744,412 votes, about 71.38% of the 394,711,296 shares outstanding as of the October 16, 2026 record date; no broker non-votes.
- Treeline merger expected to close in Q4 2026, with the Mass Cytometry sale closing substantially concurrently; CEO Michael Egholm called the votes an important step.